InMed Pharmaceuticals, Inc.

InMed Pharmaceuticals, Inc.

InMed Pharmaceuticals, Inc.

Overview
Date Founded

1981

Headquarters

200 Granville Street,Suite 340,Vancouver, BC V6C 1S4

Type of Company

Public

Employees (Worldwide)

14

Industries

Pharmaceuticals
Biotechnology

Company Description

InMed Pharmaceuticals, Inc. engages in the development of cannabinoids drug design platform. Its product pipeline includes INM-750 for the treatment of epidermolysis bullosa and INM-085 for the treatment of glaucoma. The company was founded by Christopher Bogart and Craig Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

Executives & Employees

Co-Founder

President, Chief Executive Officer & Director

Chief Financial Officer & Corporate Secretary

Chief Business Officer

Chief Medical Officer

Senior Vice President, Clinical & Regulatory Affairs

Vice President-Preclinical Research & Development

Board of Directors

Chief Financial Officer at Molecular Templates, Inc.

Vice President of Corporate Finance & Investment Banking at Eli Lilly & Company

Vice President, Global Alliance Management at Takeda Pharmaceutical Co., Ltd.

President, Chief Executive Officer & Director at InMed Pharmaceuticals, Inc.

Paths to InMed Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
InMed Pharmaceuticals, Inc.
Recent Transactions
Details Hidden

InMed Pharmaceuticals, Inc. issued Units

Details Hidden

InMed Pharmaceuticals, Inc. issued Units

Details Hidden

InMed Pharmaceuticals, Inc. purchases Biogen Sciences, Inc.

Transaction Advisors
Accountant

Advised onInMed Pharmaceuticals, Inc. purchases Eworldcentre.com from INToo Software Corp.

Underwriter

Advised onInMed Pharmaceuticals, Inc. issued Units

Legal Advisor

Advised onInMed Pharmaceuticals, Inc. issued Units

Advisors & Consultants
Scientific Advisor

Chief Scientific Officer & Montreal Site Head at Inception IBD, Inc.

Publicist

Senior Vice President, Investors Relations at Tiberend Strategic Advisors, Inc.

Publicist

Senior Account Executive at Tiberend Strategic Advisors, Inc.

Key Stats and Financials As of 2017
Market Capitalization
$141M
Total Enterprise Value
$27.2M
Earnings Per Share
$-0.05
Revenue
$0
Net Profit
$-4.47M
EBITDA
$-4.38M
Total Debt
$0
Total Equity
$7.97M
TEVNet Income
-6.07x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%